Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT.
Descriptive
Exchange
Industry
Country
Active:none
| Company | Rating | |||||
|---|---|---|---|---|---|---|
| Loading data… | ||||||
Saved screens and full data - with a subscription
Subscribe to save filters and unlock all columns and ratings.
Subscribe - €24.90/mo